A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
NCT00116779
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
127
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Degarelix
Sponsor
Ferring Pharmaceuticals